186 related articles for article (PubMed ID: 11550416)
1. Limited cutaneous systemic sclerosis: report of one case.
Lin MC; Fu LS; Huang KY; Tsen CF; Liou JM; Chi CS
Acta Paediatr Taiwan; 2001; 42(4):248-51. PubMed ID: 11550416
[TBL] [Abstract][Full Text] [Related]
2. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
[TBL] [Abstract][Full Text] [Related]
3. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
Minier T; Guiducci S; Bellando-Randone S; Bruni C; Lepri G; Czirják L; Distler O; Walker UA; Fransen J; Allanore Y; Denton C; Cutolo M; Tyndall A; Müller-Ladner U; Matucci-Cerinic M; ;
Ann Rheum Dis; 2014 Dec; 73(12):2087-93. PubMed ID: 23940211
[TBL] [Abstract][Full Text] [Related]
4. [Systemic scleroderma in children].
Plantin P; Gavanou J; Le Fur JM; Guillet G
Arch Fr Pediatr; 1988 Dec; 45(10):805-8. PubMed ID: 3266459
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's phenomenon and scleroderma.
Harper FE; LeRoy EC
Compr Ther; 1981 Feb; 7(2):45-51. PubMed ID: 6163587
[No Abstract] [Full Text] [Related]
6. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis.
Herrick AL; Cutolo M
Arthritis Rheum; 2010 Sep; 62(9):2595-604. PubMed ID: 20506306
[No Abstract] [Full Text] [Related]
8. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
Kumar N; Griffiths B; Allen J
J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
[No Abstract] [Full Text] [Related]
9. Management of systemic sclerosis--a review.
Ng SC; Clements PJ; Paulus HE
Singapore Med J; 1990 Jun; 31(3):269-72. PubMed ID: 2203150
[TBL] [Abstract][Full Text] [Related]
10. Systemic sclerosis.
Ng SC
Singapore Med J; 1992 Apr; 33(2):189-92. PubMed ID: 1621127
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
Kassamali B; Desai S; Min M; Mazori D; Villa-Ruiz C; Kus K; Cobos G; Merola J; LaChance A; Vleugels R
J Drugs Dermatol; 2021 Nov; 20(11):1257-1259. PubMed ID: 34784129
[TBL] [Abstract][Full Text] [Related]
12. Raynaud's phenomenon of the tongue.
Grémain V; Richard L; Langlois V; Marie I
Joint Bone Spine; 2017 Mar; 84(2):231. PubMed ID: 27269655
[No Abstract] [Full Text] [Related]
13. Efficacy of nifedipine in Raynaud's phenomenon associated with systemic sclerosis.
Thakur SK; Gopinathan VP; Jagdish TK; Bhalla IP; Shetty KJ
J Assoc Physicians India; 1986 Jul; 34(7):536. PubMed ID: 3759897
[No Abstract] [Full Text] [Related]
14. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Raynaud's phenomenon with captopril.
Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
[TBL] [Abstract][Full Text] [Related]
16. [Scleroderma and Raynaud's phenomenon: current pathogenetic interpretations and clinico-therapeutic trends].
Zelli GP; Cannata P
Ann Ital Chir; 1981; 53(3):337-43. PubMed ID: 7337317
[No Abstract] [Full Text] [Related]
17. [Recent advances in Raynaud's syndrome].
Klein-Weigel P
Dtsch Med Wochenschr; 2012 Mar; 137(13):622-4. PubMed ID: 22434167
[No Abstract] [Full Text] [Related]
18. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
19. Treatment of systemic sclerosis.
Wigley FM
Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
[TBL] [Abstract][Full Text] [Related]
20. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
